Abstract
The leprosy endemy in Uele, North Eastern region of Zaire has decline considerably since the 1950's, particularly since 1975. The hypothesis is advanced that the most important causal factor has been the distribution of dapsone for many years, through a vertical programme. The gradual increase of dapsone resistance has been taken care of by the introduction of combined, multidrug therapy in the 1980's. The cost per patient detected and treated rises in inverse proportion to the decline in endemy; therefore, the time has come for the integration of a leprosy control in the primary health care strategy. However, central specialized teams financed by voluntary organisations should be maintained to assure training of personnel, to give advice in diagnosis, prevention and treatment of complications, to provide drugs and to assist in rehabilitation.
Similar content being viewed by others
References
JiBaohong (1985): Drug resistance in leprosy — a review. Lepr. Rev. 56: 265–269.
Kivits M. (1955): La lutte contre la lèpre au Congo Belge - Acad. Sci. Col., 4.
PattynS.R., GroenenG., BourlandJ., GrilloneS., JanssensL. and the Collaborative Study Group for the treatment of Leprosy in Zaire and Rwanda (1987): A controlled therapeutic trial in paucibacillary leprosy comparing a single dose of rifampicin followed by 1 year of daily dapsone with 10 weekly doses of rifampicin- Lepr. Rev. 58: 349–358.
PattynS.R., GroenenG., JanssensL., DeverchinJ. and GhysP. (1989): Combined regimens of one year duration in the treatment of multibacillary leprosy II. Combined regimens with rifampicin administered during 6 months - Lepr. Rev. 60: 118–123.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tonglet, R., Pattyn, S.R., Nsansi, B.N. et al. The reduction of the leprosy endemicity in Northeastern Zaire 1975/1989. Eur J Epidemiol 6, 404–406 (1990). https://doi.org/10.1007/BF00151715
Issue Date:
DOI: https://doi.org/10.1007/BF00151715